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Abstract
HIV and AIDS remain highly stigmatised. Modified directly observed therapy (m-DOT) supports antiretroviral treatment (ART) 
adherence but little is known about its association with perceived stigma in resource-constrained settings. In 2003, 234 HIV-infected 
adults enrolled in a two-arm randomised trial comparing a health centre-based m-DOT strategy with standard self-administration 
of ART. Data on perceived stigma were collected using Berger’s HIV stigma scale prior to starting ART and after 12 months. This 
was a secondary analysis to examine whether perceived stigma was related to treatment delivery. Perceived stigma scores declined 
after 12 months of treatment from a mean of 44.9 (sd=7.6) to a mean of 41.4 (sd=7.7), (t=6.14, P<0.001). No differences were found 
between the mean scores of participants in both study arms. Also, no difference in scores was detected using GLM, controlling for 
socio-demographic characteristics and baseline scores. Findings indicate that a well managed clinic-based m-DOT does not increase 
perceived HIV-related stigma. 
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Introduction
In Kenya, there were 1.6 million adults and children living with HIV 
in 2007 (UNAIDS & WHO, 2008). As of March 2007, about half of 
the 263 000 HIV-infected individuals who required antiretroviral 
treatment (ART) had initiated it (PEPFAR, 2008). Rapid scale up of 
ART in the country began in 2004 when Kenya received nearly $92.5 
million from the Presidential Emergency Fund for AIDS Relief, in 
addition to substantial support from the Global Fund to fight AIDS, 
tuberculosis and malaria. Non-adherence to ART is a formidable 
barrier to treatment success. Health programmes in sub-Saharan 
Africa and other parts of the world still grapple with low adherence 
and drug resistance issues. Inadequate adherence is associated with 
detectable viral loads, declining CD4 counts, disease progression, 
episodes of opportunistic infections, drug resistance, poorer health 
outcomes and death (Bangsberg et al., 2006; Carpenter, Cooper, & 
Fischl, 2000; Conway, 2007; Pearson et al., 2007). Several studies have 
reported high levels of adherence across treatment programmes in 
sub-Saharan Africa (Conway, 2007; Mills, Nachega, Buchan et al., 
2006; Sarna et al., 2008). However, a systematic review by Mills, 
Nachega, Bangsberg et al. (2006) showed that non-adherence 
to ART in adult populations in a diverse range of settings varied 
between 33%-88%, depending on how adherence was defined 
and evaluated. Moreover, an increasing number of programmes 
are reporting poor retention and adherence overtime (Chen et al., 
2008; Gill, Hamer, Simon, Thea, & Sabin, 2005; Rao, Kekwaletswe, 
Hosek, Martinez, & Rodriguez, 2007; Wakabi, 2008) . Adherence 
is expected to drop as treatment expands beyond the initial select 
privileged cohorts that belonged to well funded programmes and 
those that had not started experiencing long-term side-effects of 
treatment, for example neuropathy and lipodystrophy (Bangsberg, 
Ware, & Simoni, 2006; Kip, Ehlers, & van der Wal, 2009; Malangu, 
2008; Murray et al., 2009). Conway (2007) makes a strong argument 
that sub-optimal adherence continues to be one of the most frequent 
reasons for poor treatment outcomes in ART programmes. 
Several strategies have been utilised to optimise adherence, 
for example: self-efficacy building, medication management 
skills, patient education and use of treatment buddies (Ickovics 
& Meade, 2002; Nachega et al., 2006; Remien et al., 2005; Sabin 
et al., in press; Safren, Hendriksen, Desousa, Boswell, & Mayer, 
2003; Safren et al., 2001; Samet et al., 2005; Sampaio-Sa et al., 
2008; Simoni, Amico, Pearson, & Malow, 2008; Smith, Rublein, 
Marcus, Brock, & Chesney, 2003; Tuldra et al., 2000; Weber et al., 
2004; Wong, Lawrence, Struthers, McIntyre, & Friedland, 2006). 
These strategies have mainly been evaluated in high-income 
countries. Most adherence studies in Africa have focused on 
home-based support, building self-efficacy and assessing ART 
costs and adherence (Diabate, Alary, & Koffi, 2007; Hardon et 
al., 2007; Mukherjee, Ivers, Leandre, Farmer, & Behforouz, 2006; 
Ramadhani et al., 2007; Simoni et al., 2008; Weidle et al., 2006).
Innovative strategies such as modified directly observed therapy 
(m-DOT) have been used in ART programmes to support 
adherence (Abusabha & Woelfel, 2003; Altice, Maru, Bruce, 
Springer, & Friedland, 2007; Christopher, 2006; Farmer et al., 
2001; Macalino et al., 2007; Mills, Nachega, Bangsberg et al., 2006; 
Mitchell, Freels, Creticos, Oltean, & Douglas, 2007; Munoz et al., 
in press; Page-Shipp et al., 2007; Pearson et al., 2007; Pearson 
et al., 2006). The m-DOT strategy typically involves clinic staff 
or trained peers observing patients ingesting only some of their 
ART doses while the rest of the medication is self-administered 
by the patient (Page-Shipp et al., 2007; Simoni et al., 2008). 
Observations are tapered at some point under the assumption 
that the patients have internalised the drug-taking behaviour and 
will maintain adherence to all medication without further support 
(Simoni et al., 2008). Unlike other adherence interventions, 
m-DOT helps address daily challenges to pill-taking, provides 
emotional and informational support, and is a strong link with 
health care services (Mukherjee et al., 2006). This strategy has 
been found to be feasible and successful in supporting adherence 
in community-based ART programmes in resource-constrained 
settings and for patients in closed settings such as long-term care 
facilities, prisoners and for people enrolled in methadone clinics 
in developed countries (Altice et al., 2004; Christopher, 2006; 
Farmer et al., 2001; Liechty & Bangsberg, 2003; Pearson et al., 
2007; Santos, Adeyemi, & Tenorio, 2006; Sarna et al., 2008). 
The availability of ART and subsequent change in perceptions 
of HIV and AIDS as a manageable chronic disease has led to 
a decrease in stigma and discrimination in the industrialised 
world (Herek, Capitanio, & Widaman, 2002). The situation is 
different in countries in Africa (UNAIDS, 2007) where ART has 
only recently become available to a large number of people. In 
several recent studies, people living with HIV and AIDS have still 
Résumé
Le VIH et le SIDA restent fortement stigmatisés. Le traitement modifié sous surveillance directe (m-DOT) favorise l’adhésion 
au traitement antirétroviral (ARV) mais il existe peu d’informations sur son association à la stigmatisation perçue dans des 
environnements pauvres en ressources. En 2003, 234 adultes infectés par le VIH étaient inscrits à un essai randomisé à deux bras 
comparant une stratégie m-DOT se déroulant dans un centre de santé à une auto-administration standard des ARV. Des données 
sur la stigmatisation perçue ont été collectées en utilisant l’échelle de stigmatisation du VIH de Berger avant d’entamer les ARV 
puis 12 mois plus tard. Une seconde analyse a été réalisée afin de déterminer si la stigmatisation perçue était associée au mode 
d’administration du traitement. Les résultats de la stigmatisation perçue ont baissé au bout de 12 mois de traitement, passant d’une 
moyenne de 44,9 (σ = 7,7), (t = 6,14, p<0,001) à une moyenne de 41,4 (σ =7,7), (t=6,14, p<0,001).  Aucune différence n’a été observée 
entre les résultats moyens des participants dans les deux branches de l’étude. De plus, aucune différence de résultat n’a été observée en 
utilisant le MLG, qui permet de contrôler les caractéristiques sociodémographiques et les résultats de base. Les conclusions indiquent 
qu’un m-DOT se déroulant dans un centre médical bien géré n’augmente pas la stigmatisation perçue associée au VIH. 
Mots clés: VIH/SIDA, stigmatisation perçue, attitudes, Afrique, traitement sous surveillance directe.
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reported being stigmatised, because HIV is perceived as a signal of 
immoral or deviant behaviour (Greeff & Phetlhu, 2007; Katamba 
et al., 2005; Wolfe et al., 2006). A recent qualitative study from 
Tanzania revealed that the national antiretroviral scale-up led to 
an emergence of a new source of stigma that was associated with 
ART provision (Roura et al., 2009). 
According to Goffman (1963), stigma has two components, which 
include stigma as a trait and also as an outcome of possessing 
that trait. Firstly, stigma as a trait is a characteristic that is 
viewed negatively by society, and secondly, stigma as an outcome 
occurs when the negative social meanings that are attached to 
the discrediting characteristic become labelled to an individual 
(Berger, Ferrans, & Lashley, 2001; Goffman, 1963). HIV-related 
stigmatisation is an example of this negative social labelling which 
alters the way people living with HIV are viewed and treated by 
others (enacted stigma), and how they view themselves (self-
stigma) (Thorsen, Sundby, & Martinson, 2008). In Berger and 
colleagues’ (2001) view, perceived stigma of HIV occurs in the 
context of two factors, namely: the individual’s knowledge of 
having or living with the HI virus, and her or his perception of 
societal attitudes toward people living with HIV and AIDS. Both 
views negatively affect an individual’s self concept and emotional 
reactions towards perpetrators of stigma. People with perceived 
stigma sometimes attempt to avoid or minimise actual stigma by 
closely guarding disclosure of their HIV status. 
Several studies have shown that HIV-related perceived stigma 
may result in negative health behaviour such as non-adherence, 
avoiding HIV testing, non-disclosure of HIV status and poor 
patterns of accessing health care (Dlamini et al., 2009; Greeff & 
Phetlhu, 2007; Makoae et al., 2008; Mills, Nachega, Bangsberg et al., 
2006; Mills, Nachega, Buchan et al., 2006; Nyblade & MacQuarrie, 
2006; Peltzer, Mosala, Shisana, Nqueko, & Mngqundaniso, 2007; 
Plummer et al., 2006; Pulerwitz, Michaelis, Lippman, Chinaglia, 
& Diaz, 2008; Wolfe et al., 2006). 
A literature review using search terms ‘DAART’ or ‘DOT’ or ‘ 
‘m-DOT’ and ‘HIV stigma’ or ‘perceived stigma’ or ‘internalised 
stigma’  or ‘attitude’ of the period 1980-2009 identified articles 
on the effect of DOT on study participants’ (mainly drug users) 
adherence, viral loads, CD4 cell counts and drug resistance 
(Macalino et al., 2007; Mitchell et al., 2007; Pearson et al., 2007). 
Two cross-sectional studies [in South Africa: (Page-Shipp et al., 
2007); in the US: Santos et al., 2006)] focused on attitudes to 
directly-observed ART. Some participants thought that the m-DOT 
approach was unnecessary (since they could self-administer the 
drugs) and intrusive due to loss of privacy, and interference with 
family, work or home life. However, those who wanted to receive 
m-DOT indicated that they would prefer to receive it from the 
primary health centre rather than a colleague or family member. 
They also expressed a desire for secrecy and a fear of disclosure 
beyond family members. A recent longitudinal study promoting 
adherence to ART using m-DOT strategy among Mozambicans 
did not find an increase in stigma over time (Pearson et al., in 
press). However, this study did not compare stigma between the 
m-DOT and standard-of-care arms. More recently, a community-
based DOT accompaniment cohort study in Peru by Munoz et 
al. (in press) observed a significant reduction in stigma among 
participants in the DOT arm compared to the control arm. 
We set out to explore changes in perceived stigma among a cohort 
of HIV-infected persons initiating ART in a clinic-based m-DOT 
intervention to promote adherence in Mombasa, Kenya. We 
examined perceived stigma among HIV-infected persons prior to 
starting ART and after 12 months of follow-up, and investigated 
whether m-DOT was associated with increased perceived stigma. 
The stigma study was a secondary analysis of data collected as 
part of a larger trial that was assessing the efficacy of m-DOT 
in improving adherence to ART. One key finding from this 
trial, published elsewhere, showed that adherence with m-DOT 
intervention was 4.8 times greater with adjustments for depression 
and HIV-related hospitalisations. However, the effects were not 
sustained after cessation of the intervention (Sarna et al., 2008).
Methods
Study setting and antiretroviral treatment pro-
gramme in Mombasa Kenya
In June 2003, a joint Government of Kenya (GOK) and USAID 
programme to introduce ART for the management of HIV-
infected persons was approved by the Ministry of Health (MOH) 
and began at the provincial public hospital in Mombasa (Coast 
Province General Hospital-CPGH). It was designed to serve as 
a learning site for the anticipated massive scale-up of ART in 
the public. This programme was a collaboration between the 
MOH, Family Health International (FHI), Horizons project of 
the Population Council and MSH RPMPlus Project. The MOH 
Table 1. Items from the Berger’s HIV 
stigma scalea that were used to assess per-
ceived stigma among study participants 
Items
b
Disclosure concern factors
1.   In many areas of my life no one knows I have HIV
2.   Telling some one that I have HIV is risky
3.   I work hard to keep my HIV status a secret
4.    It is easier to avoid new friendships than worry about telling 
someone that I have HIV
5.   I am very careful whom I tell that I have HIV
6.   I never feel the need to hide the fact that I have HIV (R)
Negative self-image factors
1.   I feel guilty because I have HIV
2.   Peoples’ attitude about HIV make me feel worse about myself
3.   I feel I am not as good a person as others because I have HIV
4.   I never feel ashamed of having HIV (R)
5.   Having HIV makes me feel unclean
Concern with public attitudes about people with HIV 
1.   People with HIV loose their jobs when their employers find out
2.   People with HIV are treated like outcasts
3.   Most people believe that a person who has HIV is dirty
4.   Most people are uncomfortable around someone with HIV
5.   I worry that people may judge me when they learn I have HIV
Note: 
R = reverse score
a
Berger et al., 2001
b
Participants responded using a 4-point Likert-type scale (1.Strongly disagree  2.Disagree 
3.Agree 4.Strongly agree)
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provided the human resources, existing health services (including 
medications for the management of opportunistic infections) and 
health service infrastructure. 
FHI implemented the programme and MSH RPM Plus offered 
technical advice on drug logistics and rational pharmaceutical use. 
Horizons Program (Population Council), in collaboration with 
International Centre for Reproductive Health (ICRH), designed 
and tested a two-arm randomised controlled trial comparing a 
comprehensive health centre-based m-DOT strategy to promote 
adherence with standard self-administration of ART medications 
(Sarna et al., 2008). The study was conducted at two public 
hospitals and one private (not-for-profit) hospital in Mombasa 
which is a coastal city in Kenya.
Ethical approval for the study was obtained from the national 
Kenyan ethical review committee (KNH-ERC) as well as the 
Institutional Review Board of the Population Council. Researchers 
received specific training on confidentiality and on how to 
obtain written informed consent from study participants before 
administering the questionnaires. 
Study design and procedures
Between September 2003 and November 2004, ART naïve adults 
(aged 18 years and above), living in Mombasa who were eligible 
for ART (CD4 cell count <200 cells/mm3, or WHO clinical stage 3 
or 4) were invited to participate. A sample size of 230 was chosen 
to detect a 20% difference in adherence between study groups 
(80% adherence with m-DOT versus 60% in controls) assuming 
40% death or loss to follow-up, an alpha of 0.05 and power of 0.80 
(Sarna et al., 2008). Study participants (234 total: 149 women 
and 85 men) were randomly assigned to either the m-DOT or 
standard-of-care strategies. Computer generated random-number 
assignment was used, allocating an equal number of participants 
to treatment and control groups. Allocation concealment was 
maintained with sequentially numbered, opaque sealed envelopes. 
Prior to ART initiation, participants were randomly assigned 
to study groups in blocks of 40. It was not feasible to blind the 
m-DOT strategy, given the visible and obvious nature of the 
intervention. However, laboratory personnel were blinded to the 
study group allocation. 
Treatment and care were provided within routine services at HIV 
clinics in participating facilities. Following initiation of ART, 
study participants visited treatment centres every four weeks 
for clinical follow-up. In addition to receiving standard-of-care, 
those in the intervention arm received m-DOT for a period of six 
months. This entailed twice weekly visits to a health facility, where 
participants met with a nurse who observed the ingestion of one 
dose, dispensed more medication and provided individualised 
adherence support. After six months of ART, study participants 
were changed to standard adherence case management, where 
l  l
Table 2. Characteristics of study participants at entry to the modified directly observed 
therapy trial in Kenya
Variables Total (N=183) m-DOT (n=88) Control (n=95) X² statistic P-value
Age: mean years (SD) 37.4 (7.9) 37.6 (8.3) 37.2 (7.7) 0.33* 0.74
Gender
Female 63.4 (116/183) 63.6 (56/88) 63.2 (60/95) 0.01 0.95
Marital status 
Married/cohabiting 50.0 (91/182) 48.3 (42/87) 51.6 (49/95)
Never married 11.5 (21/182) 11.5 (10/87) 11.6 (11/95)
Divorced/separated 15.4 (28/182) 12.6 (11/87) 17.9 (17/95)
Widowed 23.1 (42/182) 27.6 (24/87) 19.0 (18/95) 2.38 0.50
Highest education level
Primary/no schooling 54.7 (99/181) 57.0 (49/86) 52.6 (50/95)
Secondary education 38.1 (69/181) 39.5 (34/86) 36.8 (35/95)
Post secondary 7.2 (13/181) 3.5 (3/86) 10.5 (10/95) 3.35 0.19
Employment status
Unemployed 80.8 (147/182) 85.1 (74/87) 76.8 (73/95) 1.97 0.16
Depression
None 35.4 (63/178) 31.3 (26/83) 39.0 (37/95)
Mild 33.7 (60/178) 30.1 (25/83) 36.8 (35/95)
Moderate/severe 30.9 (55/178) 38.6 (32/83) 24.2 (23/95) 4.27 0.12
Disclosed status to regular partner 47.0 (77/164) 44.7 (34/76) 48.9 (43/88) 0.28 0.60
Gets support from family/friends 85.2 (155/182) 83.9 (73/87) 86.3 (82/95) 0.21 0.65
Duration since HIV diagnosis
≤1 year 50.3 (92/183) 50.0 (44/88) 50.5 (48/95)
>1 year 49.7 (91/183) 50.0 (44/88) 49.5 (47/95) 0.01 0.94
Number of opportunistic infections 
0-1 52.5 (96/183) 46.6 (41/88) 57.9 (55/95)
>1 47.5 (87/183) 53.4 (47/88) 42.1 (40/95) 2.34 0.13
CD4 cell count: mean cells/mm
3
 (SD) 104.1 (54.9) 109.4 (57.6) 99.2 (52.1) 1.25* 0.21
* Two independent samples t-test. SD: standard deviation. Results are % (n/N) unless stated 
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they were required to attend the clinic once a month for follow-
up and collection of a months’ supply of their medication. 
Community workers traced participants who missed visits or 
were unable to visit the health centre. In order to avoid possible 
increases in stigma resulting from home visits by community 
worker’s known to be HIV carers, participants were encouraged 
to nominate a person who would actively trace and follow them 
up if they missed a visit. Some participants preferred to be traced 
by community workers unknown in their neighbourhoods. 
Study questionnaires were translated into the local language 
(Swahili) and back translated to English. Trained researchers 
collected data using semi-structured questionnaires in face-to-
face interviews. Researchers received training on how to obtain 
information from study participants in a non-judgmental way. 
Questions included background information such as age, sex, 
education level, marital and employment status, depression, 
disclosure of HIV status, family support and history of 
opportunistic infections. 
Socio-demographic variables collected at baseline were categorised 
as follows: marital status was classified as married/cohabiting, never 
married, divorced/separated, and widowed; education as: none/
primary education (0-8 years of school attendance), secondary 
education (9-12 years), and post-secondary education (>12 
years); employment into currently employed and unemployed. 
Family support was assessed by asking participants whether 
family members supported them after disclosure of their HIV 
status, and categorised as a binary response (received support/did 
not receive support). Duration since HIV diagnosis was assessed 
by asking participants how long they had know their HIV status 
(weeks/months/years). For further analysis, this information was 
categorised as a binary response (1year or less/more than 1 year). 
The number of opportunistic infection episodes were collected 
from patients’ medical records and categorised into two groups (0 
to1 episode, or more than one episode) (see Table 2). 
Information on perceived stigma was obtained prior to the start of 
treatment and after 12 months (0 and 48 weeks; two data points). 
Perceived stigma was assessed using a 16-item scale (Cronbach’s 
alpha of adapted scale: 0.81) derived from Berger’s HIV stigma 
scale (Cronbach’s alpha: 0.96) (Berger et al., 2001), and field tested 
for translation accuracy and comprehension before use. This scale 
covered three domains: disclosure concerns (6 items); negative 
self-image (5 items); and concerns with public attitudes about 
people with HIV (5 items). The items are displayed in Table 1. 
Berger’s HIV stigma scale has four domains, but in this study the 
personalised stigma domain was not included, because similar 
questions regarding respondent’s personal experiences with 
stigma were addressed in a separate section of the questionnaire. 
The Berger scale requires participants to respond on a four-
item Likert scale (strongly disagree=1, disagree=2, agree=3 and 
strongly agree=4) to statements about their feelings and opinions 
regarding how people treated them because of their HIV status. 
The scale assesses perceived stigma cross-sectionally without a 
recall period. All items were coded so that a higher score indicated 
more stigma and vice versa. The range of possible scores for each 
item was 1 to 4; therefore, possible summed scores ranged from 
16-64. Total stigma scores were categorised into four stigma 
levels: minimal (16-28), low (29-40), moderate (41-52) and high 
(53-64). For further analysis the scores were categorised into two 
categories (minimal or low (16-40), or moderate or high stigma 
(41-64)). The change score was derived as follows: baseline stigma 
scores were subtracted from follow-up stigma scores (i.e., follow-
up score minus baseline score) to obtain the difference over the 12 
month period after initiation of ART. 
Depression was assessed at baseline, and weeks 24, 48 and 72 (four 
data points), using a culturally adapted 21 item Beck’s Depression 
Inventory version I® (Cronbach’s alpha: 0.86) translated into 
Swahili (Cronbach’s alpha for the Swahili BDI: 0.84). The tool 
assesses depression over the past four weeks. Depression was 
categorised as none (0-9), mild (10-18), moderate (19-29) 
and severe (30-63) as per BDI guidelines (Beck & Mendelson, 
1961). CD4 cell counts were determined at baseline and weeks 
24, 48 and 72 using PARTEC (four data points) using PARTEC 
(Partec-GmBH, Münster, Germany) and FACS counters (Becton 
& Dickinson Immunocytometry Systems, California, USA). For 
the stigma analysis presented in this paper only two data points 
(0 and 48 weeks) were used for all variables: perceived stigma, 
depression and CD4 counts.
Data management and analysis
Data were double-entered by separate clerks in a Microsoft Access 
2003 database and analysed using SAS version 9.1. Chi-square 
and Student’s t test were used to compare socio-demographic 
characteristics and selected variables between the groups, and to 
confirm that the randomisation procedure successfully removed 
any potential confounding factors. As outcomes were integer-level 
data (stigma scores at 12 months and change in stigma scores), 
we used generalised linear models (GLM) to assess whether 
having received m-DOT was associated with stigma scores, after 
controlling for socio-demographic characteristics and baseline 
stigma scores.
Table 3. Perceived stigma mean scores among study participants at baseline and 12 months 
after initiating antiretroviral treatment 
Variables Baseline (n=183) Follow-up  (n=183) t
a
       P-value
 Mean(SD) Mean(SD)
Total stigma score 44.9 (7.6) 41.4 (7.7)  6.14 <0.001
 Domains  
      Disclosure  17.9 (3.1) 17.2 (3.5) 2.67   0.008
      Negative self-image  12.2 (3.4) 10.4 (3.5) 6.25 <0.001
      Public attitudes  14.8 (3.1) 13.6 (3.4) 4.23 <0.001
t
a
: paired t-test            SD: standard deviation
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Results
Background characteristics of study participants
Eight of the 234 participants did not initiate ART (two withdrew 
from the study, two died, one was lost to follow-up and three could 
not participate due to severe illness). A year after ART initiation, 21 
people had died, 11 were lost to follow-up and 11 had discontinued 
study participation (five transferred to other hospitals and six 
had discontinued ART). No difference was detected between the 
baseline stigma scores of participants who completed the study, 
died or were lost to follow-up (F=2.20, P=0.114). This paper is 
based on findings from 183 study participants who had baseline 
stigma data and completed 12 months follow-up. 
Mean age of the 183 participants was 37.4 years (sd=7.9 years; 
Table 2). Sixty-three percent were female, half (50%) were married 
and about one quarter (23.1%) were widowed. There were no 
differences noted between the m-DOT and standard-of-care 
groups with regard to the socio demographics and other variables, 
as would be expected with random allocation to treatment group 
(see Table 2). 
The majority of respondents reported receiving support from 
family and friends (85.2%). However, less than half (47%) of the 
participants had disclosed their HIV status to a regular partner.
Perceived stigma
Prior to initiating treatment, about three quarters (72.2%) of 
study participants reported moderate to high levels of perceived 
stigma. There was no difference in the proportion with moderate 
or high levels of perceived stigma between the m-DOT and 
standard-of-care groups (69.8%, [60/87] versus 74.5%, [70/94]; 
P=0.48) (data not shown in tables). At the 12 month follow-up 
visit, the proportion of study participants who had moderate to 
high stigma scores declined from 72.2% (130/180) at baseline to 
56.1% (101/180; P<0.001)). Again, there was no difference noted 
between the m-DOT and standard-of-care groups (56.3% [49/87] 
versus 55.9% [52/93]; P=0.96) (data not shown in tables). 
Table 3 shows perceived stigma means scores among study 
participants at baseline and 12 months after initiating antiretroviral 
treatment. Overall, perceived stigma scores declined after 12 
months of treatment from a mean of 44.9 (sd=7.6) to a mean of 
41.4 (sd=7.7), (t=6.14, P<0.001). Results from the three stigma 
domains each followed a similar trend, with total mean scores 
declining; disclosure concerns (17.9 vs. 17.2, t=2.67, P=0.008), 
negative self-image (12.2 vs. 10.4, t=6.25, P<0.001), and public 
attitude concerns (14.8 vs. 13.6, t=4.23, P=<0.001) (see Table 3). 
No differences, however, were detected between the mean scores 
of participants in the m-DOT and standard-of-care arms (see 
Table 4).
GLM was used to analyse the relationship between m-DOT and 
perceived stigma scores. No significant association was detected 
between m-DOT and perceived stigma after controlling for age, 
sex, level of education, marital status and baseline stigma (see 
Table 5). In this analysis, the mean stigma score at 12 months 
was 0.90 higher in the m-DOT group than the controls, but the 
confidence interval included the null effect (95%CI= -1.06 to 2.87; 
P=0.36). The results were very similar when the outcome change 
in stigma score was assessed in a second GLM (data not shown). 
Mean stigma score at 12 months, however, was 4.54 points lower 
for people with post-secondary education compared with those 
with no or only primary education (95%CI= -8.58 to -0.49; 
P=0.03).  
Discussion
Our study found that m-DOT strategy did not increase perceived 
stigma among persons receiving ART. These findings were similar 
Table 4. Perceived stigma baseline, follow-up and change mean scores among study  
participants by study arms 
Variables m-DOT(n=88) Control (n=95) t
b
     P-value
 Mean(SD) Mean(SD) 
Baseline stigma 
Total stigma score 44.6 (7.7) 45.1 (7.5) -0.49 0.62
Domains
    Disclosure  17.7 (2.9) 18.2 (3.3) -1.07 0.28
    Negative self-image  12.2 (3.5) 12.1 (4.1) 0.13 0.89
    Public attitudes 14.7 (3.1) 14.8 (2.9) -0.24 0.81
Follow-up stigma
Total stigma score 41.7 (8.2) 41.1 (7.2) 0.56 0.58
Domains
   Disclosure  17.1 (3.5) 17.4 (3.5) -0.59 0.56
   Negative self-image  10.6 (3.6) 10.1 (3.4) 0.93 0.35
   Public attitudes  13.8 (3.5) 13.5 (3.4) 0.66 0.51
Change stigma
Total stigma score 2.9 (7.7) 4.0 (7.4) -1.03 0.30
Domains
   Disclosure  0.6 (3.4) 0.8 (3.6) -0.40 0.69
   Negative self-image  1.6 (3.9) 2.0 (3.9) -0.72 0.47
   Public attitudes  0.9 (3.6) 1.3 (3.5) -0.87 0.39
t
b
: Two independent samples t-test    SD: standard deviation
Original Article
68  Journal of Social Aspects of HIV/AIDS                                                                              VOL. 7 NO. 2 AUGUST 2010
to a community-based DOT cohort study in Peru (Munoz et al., 
in press) that observed a significant reduction in stigma among 
participants in the DOT arm compared to the control arm. 
Pearson and colleagues’ (in press) assessment of stigma among 
Mozambicans who had been on a one year ART regimen did not 
find a change in stigma; however, stigma increased with depression 
and decreased with disclosure of HIV status to a friend. 
Although the results from our study did not show differences 
in perceived stigma between the m-DOT and standard-of-care 
groups, overall, the level of stigma among study participants after 
12 months of ART was still high. This supports the view that HIV 
stigma remains a problem in developing countries, and that there 
is a pressing need for effective stigma reduction interventions 
to facilitate normalisation of HIV and AIDS (Greeff & Phetlhu, 
2007; Katamba et al., 2005; Munoz et al., in press; Pearson et al., 
in press; Pulerwitz et al., 2008; Sayles, Wong, Kinsler, Martins, & 
Cunningham, 2009; UNAIDS, 2007; Wolfe et al., 2006). 
A few previous studies indicated that patients did not favour 
m-DOT due to confidentiality concerns (Liechty & Bangsberg, 
2003; Page-Shipp et al., 2007; Santos et al., 2006). Therefore, 
despite the findings of our study, concerns about confidentiality, 
together with persisting high levels of stigma, show that much care 
still needs to be taken to ensure that HIV-related interventions 
do not increase stigma. Liechty and Bangsberg (2003) noted that 
both the Haitian (Farmer et al., 2001) and Rhode Island (Mitty, 
Stone, Sands, Macalino, & Flanigan, 2002) m-DOT initiatives 
were successful because the interventions were carefully designed 
to minimise stigma. In rural Haiti, accompagnateurs, who 
originally supervised therapy for tuberculosis in the 80s, delivered 
antiretroviral drugs to patients in the community, and were 
believed to be less stigmatising than witnessed dosing (Farmer 
et al., 2001). Additionally, the community-based DOT study by 
Munoz et al. (in press) used paid community health workers to 
perform DOT at home, and offered additional emotional support 
to study participants. This led to behaviour change among family 
members and providers. Another example is the m-DOT study 
in Mozambique in which researchers repositioned the HIV clinic 
entrance to a quiet corridor of the hospital prior to the start of the 
study to reduce the stigma of entering and exiting the HIV care 
facility (Pearson et al., 2006). 
There are several reasons why our m-DOT intervention did not 
increase stigma. One major plausible explanation was that our 
intervention was tailored using qualitative information from 
formative research (Sarna et al., 2008). Findings from formative 
research showed that patients preferred to select the sites where 
they would be observed ingesting their medication, and the 
community health workers who would trace them when they 
failed to show up for their clinic visits. Moreover, they confirmed 
that they wanted a family member or close friend to accompany 
them for the clinic visits. In our study, m-DOT participants were 
observed twice a week by well trained nurses in confidential 
rooms at several sites selected by patients. Home visits were 
restricted to participants who had missed clinic appointments. 
Trained community health workers, who were selected by 
patients, delivered medications and provided emotional support. 
Additionally, study participants were encouraged to bring a family 
member or friend to the twice-weekly m-DOT clinic visits and 
counselling sessions.  Our study suggests that formative research 
is useful in tailoring m-DOT to ensure that it does not increase 
stigma. Further research is needed to confirm this observation. 
Another observation that warrants further research is the 
relationship between the duration of the m-DOT and level of 
stigma. In the community-based DOT by Munoz and colleagues 
(in press), participants were supported for 12 months; with Pearson 
et al. (in press) m-DOT was done for six weeks; and our m-DOT 
intervention was conducted for six months. Does the length of 
m-DOT have an effect on perceived stigma? More research needs 
to be done to answer this pertinent question.       
Table 5. GLM analysis to assess the effect of m-DOT on perceived stigma among study  
participants after 12 months of antiretroviral treatment 
Variable Coefficient Standard error (95% CI)
   Lower Upper t  value P-value
Intercept 21.81 4.14 13.65 29.98 5.27 <0.001
Treatment Group - - -  - - -
     m-DOT 0.90 0.99 -1.06 2.87 0.91 0.36
Baseline Stigma   0.51 0.067 0.37 0.64 7.56 <0.001
Age (years)  -0.064 0.069 -0.20 0.072 -0.93 0.36
Sex
     Female (ref)  - -  - - -  -
     Male -0.59 1.18 -2.92 1.74 -0.50 0.62
Marital status
    Married/cohabit (ref)  - -  -  - - -
     Never married -1.17 1.60  -4.33 1.99 -0.73 0.46
     Divorced/separated    1.50 1.46 -1.38 4.38 1.03 0.31
     Widowed   0.94 1.35 -1.73 3.61 0.69 0.49
Highest education level
   No schooling/primary(ref) - - - - - -
   Secondary -1.74 1.08 -3.87 0.39 -1.61 0.11
   Post secondary -4.54 2.05 -8.58 -0.49 -2.21 0.028
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This study has several limitations. First, some aspects of stigma 
may be specific to local settings, limiting the generalisability of 
the findings. Second, the study was done in a health facility, and 
it is therefore uncertain whether we would find similar findings if 
m-DOT services were primarily community-based. Third, given 
that each patient only received six months of m-DOT services, 
more research is needed to assess the impact of a longer m-DOT 
intervention on perceived stigma. Fourth, the Berger HIV stigma 
scale mainly measures perceived stigma and may not capture 
compound or layered stigma (Nyblade, 2006). Fifth, the follow-
up data collection exercise was done six months after the m-DOT 
intervention had been completed, and the time lag between 
measures could have influenced our findings to some extent. 
A dedicated m-DOT stigma study is warranted to explore the 
relationship of stigma and the duration of m-DOT implemented 
in clinic- and community-based settings. 
The larger RCT demonstrated that the use of m-DOT did 
increase adherence; and evidence from this secondary analysis 
indicates that perceived stigma did not increase post m-DOT. 
These findings suggest that m-DOT could be a useful strategy to 
improve adherence in resource constrained settings. 
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